Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study

NCT04676971 is registered in ClinicalTrials.gov with ImmuneMed, Inc. as lead sponsor.

NCT NCT04676971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study
Lead sponsor
ImmuneMed, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2020
Completion date
October 28, 2021
Enrollment
115 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19